Sobi enters new credit facility and redeems SEK 800 M bond loan 2012/2017 prior to final maturity
Swedish Orphan Biovitrum AB (publ) (Sobi™) has a SEK 800 million bond loan with a final maturity on 27 June 2017 (the “Bond Loan”). The Bond Loan has a floating rate coupon of STIBOR 3 months plus 5 per cent per year. Sobi hereby irrevocably gives notice that it will redeem the Bond Loan on 27 June 2016 in advance of its final maturity.
To redeem the Bond Loan, Sobi has entered into a three year SEK 500 million term and SEK 500 million revolving facilities agreement with Svenska Handelsbanken AB (publ) and Danske Bank A/S, Danmark, Sverige Filial. Part of the facility will be used, together with own funds, to redeem the Bond Loan on 27 June 2016 in accordance with Clause 7.4 of the terms and conditions of the Bond Loan. Each Bond will be redeemed at a redemption amount equal to 101 per cent of its nominal amount together with accrued but unpaid interest.
Payment will be made to all who, in accordance with the terms and conditions of the Bond Loan, are registered as “Bondholder” on 17 June 2016.
This notice of early redemption is irrevocable.
Sobi™ is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ Stockholm.
For more information please contact
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
The information set out in this press release is announced in accordance with the Swedish Securities Market Act. The information was submitted for publication on 27 May 2016 at 08:00 CET.